BIO — Bio Rad Laboratories Balance Sheet
0.000.00%
Last trade - 00:00
- $7.87bn
- $7.46bn
- $2.67bn
- 86
- 57
- 40
- 64
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,115 | 991 | 870 | 1,791 | 1,607 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 393 | 419 | 424 | 495 | 489 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 2,180 | 2,140 | 1,990 | 3,158 | 3,048 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 701 | 694 | 716 | 680 | 724 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 8,009 | 12,973 | 17,799 | 13,502 | 12,299 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 905 | 632 | 681 | 569 | 523 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 2,254 | 3,093 | 4,114 | 3,886 | 3,558 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 5,755 | 9,880 | 13,685 | 9,615 | 8,741 |
Total Liabilities & Shareholders' Equity | 8,009 | 12,973 | 17,799 | 13,502 | 12,299 |
Total Common Shares Outstanding |